Drug intelligence / Profile preview

Morinamide

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

Morinamide is a small molecule, second-line antituberculosis agent classified as a pyrazinecarboxamide. It is used in the treatment of tuberculosis and acts as a prodrug for pyrazinamide. Its primary mechanism of action involves inhibition of mycolic acid synthesis by targeting fatty acid synthase II (FAS-II), which disrupts the integrity of the Mycobacterium tuberculosis cell wall, leading to bacteriostatic and bactericidal effects. The drug’s efficacy is pH-dependent, with optimal activity at acidic pH (around 5.6). Morinamide is typically administered orally as its hydrochloride salt.

Brand names: Piazofolina
Other names: Morinamida952-54-5

Targets

FAS-I (Mycobacterial fatty acid synthase I complex)MmpL3 (Mycobacterial membrane protein Large 3)

Beyond the preview

Go deeper on Morinamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Morinamide.

Explore the full profile